CONTACT
+91 80 2808 2808
ContactUs.BBL@biocon.com

DIABETOLOGY

Diabetology

Biocon Biologics has one of the deepest portfolios of biosimilars in the industry. Our long-term investments in R&D have yielded several molecules in diabetes, of which two have already been commercialized in across markets globally.

Glargine 100U

Approved: Registered in 70+ countries across the globe, including the U.S., Europe, Japan, Canada, Australia, several markets across most of the world (MoW)

Launched: Commercialized in the U.S., Europe, Australia, India, Malaysia, Egypt, Morocco, Mexico etc

Preclinical

Clinical

Filed

Approved

Launched

Glargine 300U

Preclinical

Clinical

Filed

Approved

Launched

Share